Clinical trial
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
NCT07327840 is registered in ClinicalTrials.gov with Kylonova (Xiamen) Biopharma co., LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
- Lead sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 29, 2025
- Completion date
- August 31, 2028
- Enrollment
- 204 (estimated)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.
lipoprotein disorder